November 12th 2018

Colon cancer is hitting younger people and obesity may be to blame

Colorectal cancer is starting younger — and growing obesity rates may be the reason. Last year, the American Cancer Society found the disease was occurring among people in their 20s and 30s at a rate of one to two per cent higher than in the mid-1990s. US research suggests that people born in 1990 and later now have double the risk of colon cancer of those born around 1950. Read more

 

October 4th 2018

Rhythm Biosciences hits development milestone for its cancer diagnostic

Colorectal cancer is the third most common type of cancer but now, one ASX-listed biotech is one step closer to commercialising an important diagnostic tool. Melbourne-based Rhythm Biosciences is developing a blood test called ColoSTAT. It uses antibodies to measure the levels of a small panel of proteins in the blood that vary in the presence or absence of colorectal cancer. Read more

 

October 24th 2018

Could co-marketing be a way for Rhythm Bio to get its test out there

A co-promotion deal could be a novel way for Aussie colon cancer play Rhythm Biosciences to get its blood test into the market, without having to set up an expensive sales network. CEO and managing director Dr Trevor Lockett says they’re considering a number of methods to commercialise their technology and believes a recent co-marketing deal in the US demonstrates an interesting option. Read more

 

September 17th 2018

Bowel cancer is rising in Asia but Rhythm Bio may be able to help

Colorectal cancer is traditionally seen as an issue in western countries, but it is a growing problem in the Asia Pacific and developing countries as well. “The five-year prevalence population for colorectal cancer in the Asia-Pacific was 1.7 million in 2017,” according to a study by Research and Markets. South Korea and China have steadily rising rates of colorectal cancer. While the latter still has lower rates of incidence than in the West, people with the disease were much more likely to die from it. Read more